Log in

NASDAQ:CORT - Corcept Therapeutics Stock Price, Forecast & News

$13.59
-0.07 (-0.51 %)
(As of 02/23/2020 02:58 PM ET)
Today's Range
$13.50
Now: $13.59
$14.37
50-Day Range
$11.86
MA: $12.96
$14.04
52-Week Range
$9.55
Now: $13.59
$17.48
Volume1.20 million shs
Average Volume805,427 shs
Market Capitalization$1.55 billion
P/E Ratio17.42
Dividend YieldN/A
Beta1.25
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$306.49 million
Cash Flow$0.65 per share
Book Value$2.39 per share

Profitability

Net Income$75.41 million

Miscellaneous

Employees166
Market Cap$1.55 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.


Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Thursday, February, 20th. The biotechnology company reported $0.24 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.24. The biotechnology company had revenue of $87.90 million for the quarter, compared to analysts' expectations of $87.85 million. Corcept Therapeutics had a net margin of 30.73% and a return on equity of 30.77%. The business's revenue for the quarter was up 31.6% on a year-over-year basis. During the same period last year, the firm earned $0.18 earnings per share. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Corcept Therapeutics.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $350.85 million.

What price target have analysts set for CORT?

3 Wall Street analysts have issued 1-year price objectives for Corcept Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Corcept Therapeutics' stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.

What is the consensus analysts' recommendation for Corcept Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics.

What are Wall Street analysts saying about Corcept Therapeutics stock?

Here are some recent quotes from research analysts about Corcept Therapeutics stock:
  • 1. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug Korlym. The drug has witnessed higher sales and strong uptake since its approval. Korlym’s label expansion programs are also promising and should boost its commercial potential in future quarters. Corcept's most advanced candidate relacorilant is currently under evaluation in a phase III study for Cushing's syndrome. The successful development of its pipeline candidates will further boost the company’s growth and lead to increased sales. However, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future. Shares have outperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings release. Corcept has a positive record of earnings surprises in recent quarters." (2/4/2020)
  • 2. Cantor Fitzgerald analysts commented, "We have a N rating & a $14 PT for CORT based on our valuation of the Korlym + Rela’ franchise. We believe it’s about Rela’ and our question is when will it successfully complete the P3 in Cushing’s & displace Korlym? This thesis is our primary focus since it announced lower-than-projected Korlym rev for 4Q18 & 2019 guidance that points to limited upside potential (~20% midpoint of $285-315M)." (5/1/2019)

Has Corcept Therapeutics been receiving favorable news coverage?

Media coverage about CORT stock has been trending very negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Corcept Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Corcept Therapeutics.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), CA (CA), BlackRock (BLK), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Alibaba Group (BABA), Endologix (ELGX), Energy Transfer LP Unit (ET) and Celgene (CELG).

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
  • Mr. Gary Charles Robb, CFO & Sec. (Age 56)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (7.01%), Renaissance Technologies LLC (6.80%), State Street Corp (2.65%), LSV Asset Management (1.50%), Geode Capital Management LLC (1.25%) and Parallel Advisors LLC (1.23%). Company insiders that own Corcept Therapeutics stock include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.

Which institutional investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Marshall Wace LLP, PNC Financial Services Group Inc., AJO LP, State of New Jersey Common Pension Fund D, Bank of America Corp DE, AQR Capital Management LLC and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Corcept Therapeutics.

Which institutional investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, LSV Asset Management, Man Group plc, Mackay Shields LLC, First Trust Advisors LP, Goldman Sachs Group Inc., California Public Employees Retirement System and Parallel Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $13.59.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.55 billion and generates $306.49 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.View Additional Information About Corcept Therapeutics.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is http://www.corcept.com/.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  380 (Vote Underperform)
Total Votes:  834
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel